Workflow
Weihai Baihe Biology Technological (603102)
icon
Search documents
百合股份(603102) - 百合股份2024年1月投资者关系活动记录表
2024-01-31 10:11
威海百合生物技术股份有限公司 投资者关系活动记录表 证券简称:百合股份 证券代码:603102 编号:2024-001 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 动类别 □新闻发布会 □路演活动 现场参观 □其他(请文字说明其他活动内容) 国联证券:邓洁 宝盈基金:张若伦 诺安基金:李新帜 大家资产:李德宝 方正富邦:庄英杰 中信建投:张立、高畅 长城证券:刘鹏 参与单位名称 中邮基金:綦征 及人员姓名 申万宏源:熊智超 英大资产:孙颖 长江证券:陈硕旸 徐爽 方正证券:谌保罗 国盛证券:陈熠 德邦证券:韦香怡 泰德圣投资:徐正敏 鹏华基金:陈金伟、赵璐 2024年1月9日10:00-15:00现场参观 2024年1月18日13:00-15:00现场参观 时间 2024年1月19日13:00-15:00现场参观 ...
百合股份:威海百合生物技术股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
2024-01-02 07:48
证券代码:603102 证券简称:百合股份 公告编号:2024-001 威海百合生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●截至 2023 年 12 月 31 日,威海百合生物技术股份有限公司(以下简称"公 司") 通过上海证券交易所系统以集中竞价交易方式回购公司 A 股普通股股票 1,000,000 股,占公司当前总股本的比例为 1.56%,回购的最高成交价格为人民币 39.50 元/股,最低成交价格为人民币 36.94 元/股,支付的资金总额为人民币 38,237,128.76 元(不含印花税、交易佣金等交易费用)。 一、回购股份的基本情况 公司于 2023 年 3 月 24 日召开第四届董事会第三次会议,审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》,同意公司以自有或自筹资金以 集中竞价交易方式回购部分公司股份,本次回购股份将在未来适宜时机全部用于 员工持股计划或股权激励,回购价格不超过人民币 50 元/股(含),回购 ...
百合股份:威海百合生物股份技术有限公司股东减持股份结果公告
2023-12-25 08:11
证券代码:603102 证券简称:百合股份 公告编号:2023-055 威海百合生物技术股份有限公司 股东减持股份结果公告 | 股东名称 | 股东身份 | 持股数量(股) | 持股比例 | 当前持股股份来源 | | | --- | --- | --- | --- | --- | --- | | 广发信德 | 5%以下股东 | 644,100 | 1.01% | 前取得:644,100 IPO | 股 | 上述减持主体无一致行动人。 二、减持计划的实施结果 (一)股东因以下事项披露减持计划实施结果: 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 股东持股的基本情况 截至本公告披露之日,广发信德投资管理有限公司(以下简称"广发信德") 持有威海百合生物技术股份有限公司(以下简称"公司")股份 0 股,占公司总股 本的 0.00%。 减持计划的实施结果情况 公司于 2023 年 12 月 20 日披露了《股东减持股份计划公告》(公告编号: 2023-054),广发信德计划自减持计划公告之日起 3 个交易日 ...
百合股份:威海百合生物技术股份有限公司股东减持股份计划公告
2023-12-19 11:07
证券代码:603102 证券简称:百合股份 公告编号:2023-054 威海百合生物技术股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 股东持股的基本情况 截至本公告披露之日,广发信德投资管理有限公司(以下简称"广发信德") 持有公司股份 644,100 股,占公司总股本的 1.01%,上述股份全部来源于公司首 次公开发行股票前已持有的股份。 减持计划的主要内容 广发信德计划自本减持计划公告之日起 3 个交易日之后的三个月内,通过大 宗交易方式减持公司股份不超过 644,100 股,不超过公司总股本的 1.01%。若在 减持计划实施期间公司发生送股、资本公积金转增股本等股份变动事项,广发信 德可以根据公司股本变动对减持计划进行相应调整。 公司于 2023 年 12 月 19 日收到股东广发信德出具的《股份减持计划告知 函》,现将有关减持计划公告如下: 上述减持主体无一致行动人。 二、减持计划的主要内容 | 股东 | | 计划减持数 | 计划减持 | 减持方式 | 竞 ...
百合股份:威海百合生物技术股份有限公司关于以集中竞价交易方式回购股份达到总股本1%暨回购股份进展的公告
2023-12-18 08:19
证券代码:603102 证券简称:百合股份 公告编号:2023-053 本次回购方案的实施情况:截至 2023 年 12 月 18 日,威海百合生物技术股 份有限公司(以下简称"公司")通过上海证券交易所系统以集中竞价交易方式 已累计回购公司A股普通股股票750,400股,占公司当前总股本的比例为1.17%, 与上次披露数相比增加 0.37%,回购的最高成交价格为人民币 39.50 元/股,最低 成交价格为人民币 37.61 元/股,已支付的资金总额为人民币 28,817,514 元(不含 印花税、交易佣金等交易费用)。 一、回购股份的基本情况 公司于 2023 年 3 月 24 日召开第四届董事会第三次会议,审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》,同意公司以自有或自筹资金以 集中竞价交易方式回购部分公司股份,本次回购股份将在未来适宜时机全部用于 员工持股计划或股权激励,回购价格不超过人民币 50 元/股(含),回购资金总 额不低于人民币 3,000 万元(含),不超过人民币 6,000 万元(含),回购期限 为自董事会审议通过本次回购方案之日起 12 个月内,具体内容详见公司在上海 证 ...
百合股份:威海百合生物技术股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
2023-12-01 07:36
证券代码:603102 证券简称:百合股份 公告编号:2023-052 威海百合生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●截至 2023 年 11 月 30 日,威海百合生物技术股份有限公司(以下简称"公 司") 通过上海证券交易所系统以集中竞价交易方式首次回购公司 A 股普通股 股票 512,500 股,占公司当前总股本的比例为 0.80%,回购的最高成交价格为人 民币 39.50 元/股,最低成交价格为人民币 37.61 元/股,支付的资金总额为人民币 19,729,153.00 元(不含印花税、交易佣金等交易费用)。 一、回购股份的基本情况 公司于 2023 年 3 月 24 日召开第四届董事会第三次会议,审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》,同意公司以自有或自筹资金以 集中竞价交易方式回购部分公司股份,本次回购股份将在未来适宜时机全部用于 员工持股计划或股权激励,回购价格不超过人民币 50 元/股(含), ...
百合股份:威海百合生物技术股份有限公司关于召开2023年第三季度业绩说明会的公告
2023-11-17 07:54
证券代码:603102 证券简称:百合股份 公告编号:2023-051 威海百合生物技术股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 投资者可于 2023 年 11 月 26 日(星期日)16:00 前通过公司邮箱 suntongbo@sohu.com 进行提问,公司将在业绩说明会上对投资者普遍关注的问 题进行回答。 威海百合生物技术股份有限公司(以下简称"公司")已于 2023 年 10 月 25 日发布公司 2023 年第三季度报告,为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财务状况,公司计划于 2023 年 11 月 27 日(星期一) 下午 15:00-16:00 举行 2023 年第三季度业绩说明会,就投资者关心的问题进行交 流。 一、说明会类型 本次业绩说明会以网络互动形式召开,公司将针对 2023 年第三季度的经营 成果、财务指标的具体情况与投资者进行互动交流和沟通,在信息披露允许的范 围内就投资者普遍关注的 ...
百合股份:威海百合生物技术股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
2023-10-31 08:08
证券代码:603102 证券简称:百合股份 公告编号:2023-050 威海百合生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●截至 2023 年 10 月 31 日,威海百合生物技术股份有限公司(以下简称"公 司") 通过上海证券交易所系统以集中竞价交易方式首次回购公司 A 股普通股 股票 512,500 股,占公司当前总股本的比例为 0.80%,回购的最高成交价格为人 民币 39.50 元/股,最低成交价格为人民币 37.61 元/股,支付的资金总额为人民币 19,729,153.00 元(不含印花税、交易佣金等交易费用)。 一、回购股份的基本情况 公司于 2023 年 3 月 24 日召开第四届董事会第三次会议,审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》,同意公司以自有或自筹资金以 集中竞价交易方式回购部分公司股份,本次回购股份将在未来适宜时机全部用于 员工持股计划或股权激励,回购价格不超过人民币 50 元/股(含), ...
百合股份:威海百合生物技术股份有限公司关于以集中竞价交易方式首次回购公司股份的公告
2023-10-25 08:26
证券代码:603102 证券简称:百合股份 公告编号:2023-049 一、回购股份的基本情况 公司于 2023 年 3 月 24 日召开第四届董事会第三次会议,审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》,同意公司以自有或自筹资金以 集中竞价交易方式回购部分公司股份,本次回购股份将在未来适宜时机全部用于 员工持股计划或股权激励,回购价格不超过人民币 50 元/股(含),回购资金总 额不低于人民币 3,000 万元(含),不超过人民币 6,000 万元(含),回购期限 为自董事会审议通过本次回购方案之日起 12 个月内,具体内容详见公司在上海 证券交易所网站(www.sse.com.cn)披露的《关于以集中竞价交易方式回购公司 股份方案的公告》(公告编号:2023-013)和《关于以集中竞价交易方式回购公 司股份的回购报告书》(公告编号:2023-016)。 二、首次实施回购股份的情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定,现将公司首次回购股份情况公告如下: 2023 年 10 月 25 日,公司通过上海证券交易所系统以集中竞价交易方 ...
百合股份(603102) - 2023 Q3 - 季度财报
2023-10-24 16:00
[Important Notice](index=1&type=section&id=Important%20Notice) This report confirms the board, supervisory board, and senior management's assurance of the quarterly report's truthfulness, accuracy, and completeness, with financial statements unaudited - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report content and assume legal responsibility[2](index=2&type=chunk) - The company's head, chief accountant, and head of accounting department guarantee the truthfulness, accuracy, and completeness of the financial information in the quarterly report[3](index=3&type=chunk) - The financial statements for the third quarter are unaudited[4](index=4&type=chunk) [Key Financial Data](index=1&type=section&id=一.%20Key%20Financial%20Data) The company demonstrated robust financial growth in the first three quarters of 2023, with double-digit increases in revenue and net profit, alongside significantly improved operating cash flow [(I) Key Accounting Data and Financial Indicators](index=1&type=section&id=%28一%29Key%20Accounting%20Data%20and%20Financial%20Indicators) Q1-Q3 2023 saw over 20% growth in revenue and net profit, with operating cash flow up 51.85%, despite a slight Q3 decline, while total assets and equity increased Key Financial Indicators for Q3 and YTD 2023 | Item | Current Period (Q3) | YoY Change (%) | YTD | YTD YoY Change (%) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 184,591,377.73 CNY | -3.45 | 632,508,118.64 CNY | 21.82 | | Net Profit Attributable to Shareholders | 31,241,042.11 CNY | -10.69 | 128,704,815.37 CNY | 20.68 | | Net Profit Attributable to Shareholders Excluding Non-Recurring Gains/Losses | 29,627,135.10 CNY | -11.89 | 119,659,191.43 CNY | 17.37 | | Net Cash Flow from Operating Activities | Not applicable | Not applicable | 139,715,537.99 CNY | 51.85 | | Basic Earnings Per Share (CNY/share) | 0.49 | -10.91 | 2.01 | 17.54 | | Diluted Earnings Per Share (CNY/share) | 0.49 | -10.91 | 2.01 | 17.54 | | Weighted Average Return on Net Assets (%) | 2.09 | Decrease of 0.46 percentage points | 8.76 | Increase of 0.48 percentage points | | **End of Current Period** | | | **End of Prior Year** | **Change from Prior Year-End (%)** | | Total Assets | 1,712,922,553.72 CNY | | 1,661,982,995.88 CNY | 3.06 | | Total Owners' Equity Attributable to Shareholders | 1,512,363,829.22 CNY | | 1,422,049,161.75 CNY | 6.35 | [(II) Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=%28二%29Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for Q1-Q3 2023 were **CNY 9,045,623.94**, mainly from government grants and entrusted investments Non-Recurring Gains and Losses Items for Q3 and YTD 2023 | Item | Amount for Current Period (Q3) | Amount YTD | | :--- | :--- | :--- | | Gains/losses on disposal of non-current assets | 33,082.91 CNY | 55,399.54 CNY | | Government grants recognized in current profit/loss | 892,500.87 CNY | 9,276,844.68 CNY | | Gains/losses from entrusted investments or asset management | 365,479.45 CNY | 842,191.78 CNY | | Other non-operating income and expenses apart from the above | 438,883.82 CNY | 77,305.11 CNY | | Other profit/loss items meeting the definition of non-recurring gains/losses | - | 143,220.99 CNY | | Less: Income tax impact | 116,040.04 CNY | 1,349,338.16 CNY | | Total | 1,613,907.01 CNY | 9,045,623.94 CNY | [(III) Changes in Key Accounting Data and Financial Indicators and Their Reasons](index=3&type=section&id=%28三%29Changes%20in%20Key%20Accounting%20Data%20and%20Financial%20Indicators%20and%20Their%20Reasons) Net cash flow from operating activities increased by **51.85%** YTD, primarily due to higher sales collections from revenue growth - Net cash flow from operating activities increased by **51.85%** YTD, primarily due to increased sales collections resulting from revenue growth[8](index=8&type=chunk) [Shareholder Information](index=3&type=section&id=二.%20Shareholder%20Information) As of the reporting period, the company had 9,209 common shareholders, with **Liu Xinli** as the largest at **40.94%**, indicating high equity concentration [(I) Total Number of Common Shareholders, Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Holdings](index=3&type=section&id=%28一%29Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) The company had **9,209** common shareholders; **Liu Xinli** held **40.94%** of restricted shares, while **Liu Luzeng** led unrestricted shareholders - The total number of common shareholders at the end of the reporting period was **9,209**[10](index=10&type=chunk) Top 10 Shareholders' Holdings | Shareholder Name | Shareholder Nature | Number of Shares Held | Shareholding Percentage (%) | Number of Restricted Shares Held | Pledge, Mark, or Freeze Status | | :--- | :--- | :--- | :--- | :--- | :--- | | Liu Xinli | Domestic Natural Person | 26,198,803 | 40.94 | 26,198,803 | None | | Liu Zhaomin | Domestic Natural Person | 1,936,742 | 3.03 | 1,936,742 | None | | Liu Luzeng | Domestic Natural Person | 1,710,730 | 2.67 | 0 | None | | Wang Wentong | Domestic Natural Person | 1,697,518 | 2.65 | 0 | None | | Liu Xinzhi | Domestic Natural Person | 1,375,005 | 2.15 | 0 | None | | Industrial and Commercial Bank of China Co., Ltd. - GF Multi-Factor Flexible Allocation Mixed Securities Investment Fund | Other | 1,065,800 | 1.67 | 0 | None | | Tian Shuning | Domestic Natural Person | 986,138 | 1.54 | 0 | None | | Ge Yongle | Domestic Natural Person | 965,726 | 1.51 | 0 | None | | Zheng Zhihai | Domestic Natural Person | 910,029 | 1.42 | 0 | None | | Yantai Chunhua Investment Co., Ltd. | Domestic Non-State-Owned Legal Person | 887,000 | 1.39 | 0 | None | - Liu Zhaomin is the brother of Liu Xinli, the company's actual controller, chairman, and general manager's spouse; GF Xinde Investment Management Co., Ltd. is a wholly-owned subsidiary of GF Securities Co., Ltd[11](index=11&type=chunk) [Other Reminders](index=4&type=section&id=三.%20Other%20Reminders) No other significant operational information requiring investor attention was identified during the reporting period - There is no other significant operational information in the reporting period that requires investors' attention[12](index=12&type=chunk) [Quarterly Financial Statements](index=4&type=section&id=四.%20Quarterly%20Financial%20Statements) This chapter presents unaudited consolidated and parent company financial statements, including balance sheets, income statements, and cash flow statements, with new accounting standard adjustments [(I) Type of Audit Opinion](index=4&type=section&id=%28一%29Type%20of%20Audit%20Opinion) The financial statements for the current quarter are unaudited - The financial statements for the current quarter are unaudited[12](index=12&type=chunk) [(II) Financial Statements](index=4&type=section&id=%28二%29Financial%20Statements) This section presents the consolidated and parent company balance sheets as of September 30, 2023, and income and cash flow statements for Q1-Q3 2023 [Consolidated Balance Sheet](index=4&type=section&id=Consolidated%20Balance%20Sheet) As of September 30, 2023, consolidated total assets reached **CNY 1.71 billion**, up **3.06%** from 2022 year-end, with total equity at **CNY 1.51 billion** Consolidated Balance Sheet Key Data (As of September 30, 2023) | Item | September 30, 2023 (CNY) | December 31, 2022 (CNY) | | :--- | :--- | :--- | | Cash and cash equivalents | 1,077,007,451.47 | 1,099,672,813.40 | | Inventories | 123,826,400.52 | 147,076,150.21 | | Total current assets | 1,308,581,305.11 | 1,307,447,191.14 | | Fixed assets | 318,789,259.91 | 295,135,524.87 | | Intangible assets | 45,029,746.41 | 27,151,715.63 | | Total non-current assets | 404,341,248.61 | 354,535,804.74 | | **Total Assets** | **1,712,922,553.72** | **1,661,982,995.88** | | Accounts payable | 76,652,243.84 | 98,628,162.51 | | Contract liabilities | 54,475,648.05 | 68,249,793.68 | | Total current liabilities | 179,637,619.79 | 217,087,361.77 | | Total non-current liabilities | 20,921,104.71 | 22,846,472.36 | | **Total Liabilities** | **200,558,724.50** | **239,933,834.13** | | Total owners' equity attributable to parent company | 1,512,363,829.22 | 1,422,049,161.75 | | **Total Liabilities and Owners' Equity** | **1,712,922,553.72** | **1,661,982,995.88** | [Consolidated Income Statement](index=7&type=section&id=Consolidated%20Income%20Statement) Q1-Q3 2023 consolidated total operating revenue grew **21.82%** to **CNY 632.5 million**, with net profit attributable to parent company shareholders up **20.68%** Consolidated Income Statement Key Data (January-September 2023) | Item | Q1-Q3 2023 (CNY) | Q1-Q3 2022 (CNY) | | :--- | :--- | :--- | | Total operating revenue | 632,508,118.64 | 519,223,878.36 | | Total operating costs | 489,418,967.56 | 395,674,918.47 | | Including: Operating costs | 384,336,861.81 | 324,558,581.97 | | Selling expenses | 61,959,603.60 | 39,668,230.83 | | Administrative expenses | 27,784,615.19 | 26,368,033.63 | | R&D expenses | 22,189,419.71 | 15,289,353.29 | | Financial expenses | -11,860,861.07 | -13,524,201.02 | | Operating profit | 147,450,094.23 | 123,112,000.39 | | Total profit | 147,527,399.34 | 123,102,979.39 | | Net profit | 128,704,815.37 | 106,646,743.71 | | Net profit attributable to parent company shareholders | 128,704,815.37 | 106,646,743.71 | | Basic earnings per share (CNY/share) | 2.01 | 1.71 | | Diluted earnings per share (CNY/share) | 2.01 | 1.71 | [Consolidated Cash Flow Statement](index=10&type=section&id=Consolidated%20Cash%20Flow%20Statement) Q1-Q3 2023 net operating cash flow surged **51.85%** to **CNY 139.7 million**, while investing and financing activities resulted in net outflows Consolidated Cash Flow Statement Key Data (January-September 2023) | Item | Q1-Q3 2023 (CNY) | Q1-Q3 2022 (CNY) | | :--- | :--- | :--- | | Subtotal cash inflows from operating activities | 682,107,347.40 | 552,685,356.96 | | Subtotal cash outflows from operating activities | 542,391,809.41 | 460,676,051.05 | | Net cash flow from operating activities | 139,715,537.99 | 92,009,305.91 | | Subtotal cash inflows from investing activities | 10,912,668.36 | 7,024,940.21 | | Subtotal cash outflows from investing activities | 136,170,926.30 | 55,382,361.65 | | Net cash flow from investing activities | -125,258,257.94 | -48,357,421.44 | | Subtotal cash inflows from financing activities | - | 616,056,184.48 | | Subtotal cash outflows from financing activities | 38,400,000.00 | 44,903,665.00 | | Net cash flow from financing activities | -38,400,000.00 | 571,152,519.48 | | Net increase in cash and cash equivalents | -22,665,361.93 | 622,189,485.02 | | Cash and cash equivalents at end of period | 1,077,007,451.47 | 1,036,364,279.18 | [Parent Company Balance Sheet](index=11&type=section&id=Parent%20Company%20Balance%20Sheet) As of September 30, 2023, parent company total assets were **CNY 1.72 billion**, a slight increase from 2022 year-end, with total equity at **CNY 1.52 billion** Parent Company Balance Sheet Key Data (As of September 30, 2023) | Item | September 30, 2023 (CNY) | December 31, 2022 (CNY) | | :--- | :--- | :--- | | Cash and cash equivalents | 1,076,787,013.29 | 1,099,598,819.21 | | Total current assets | 1,311,170,067.92 | 1,310,790,767.06 | | Total non-current assets | 408,380,905.50 | 360,747,474.20 | | **Total Assets** | **1,719,550,973.42** | **1,671,538,241.26** | | Total current liabilities | 179,606,917.42 | 218,011,363.57 | | Total non-current liabilities | 20,921,104.71 | 22,846,472.36 | | **Total Liabilities** | **200,528,022.13** | **240,857,835.93** | | Total owners' equity | 1,519,022,951.29 | 1,430,680,405.33 | | **Total Liabilities and Owners' Equity** | **1,719,550,973.42** | **1,671,538,241.26** | [Parent Company Income Statement](index=14&type=section&id=Parent%20Company%20Income%20Statement) Q1-Q3 2023 parent company operating revenue reached **CNY 632.6 million**, with net profit attributable to shareholders at **CNY 126.7 million** Parent Company Income Statement Key Data (January-September 2023) | Item | Q1-Q3 2023 (CNY) | Q1-Q3 2022 (CNY) | | :--- | :--- | :--- | | Operating revenue | 632,576,925.95 | 519,212,778.41 | | Operating costs | 384,413,218.89 | 324,733,211.85 | | Selling expenses | 63,563,144.83 | 40,303,181.51 | | Administrative expenses | 26,308,842.59 | 24,708,327.91 | | R&D expenses | 22,189,419.71 | 15,289,353.29 | | Financial expenses | -11,862,204.21 | -13,527,419.72 | | Operating profit | 146,084,557.55 | 124,181,188.84 | | Total profit | 145,570,735.59 | 124,172,167.84 | | Net profit | 126,732,693.86 | 107,696,427.17 | [Parent Company Cash Flow Statement](index=15&type=section&id=Parent%20Company%20Cash%20Flow%20Statement) Q1-Q3 2023 parent company net operating cash flow significantly increased to **CNY 139.6 million**, with net outflows from investing and financing activities Parent Company Cash Flow Statement Key Data (January-September 2023) | Item | Q1-Q3 2023 (CNY) | Q1-Q3 2022 (CNY) | | :--- | :--- | :--- | | Net cash flow from operating activities | 139,560,340.00 | 91,827,093.25 | | Net cash flow from investing activities | -125,249,503.94 | -48,358,368.06 | | Net cash flow from financing activities | -38,400,000.00 | 571,152,519.48 | | Net increase in cash and cash equivalents | -22,811,805.92 | 622,006,325.74 | | Cash and cash equivalents at end of period | 1,076,787,013.29 | 1,036,157,041.84 | [Adjustments to Opening Financial Statements Due to First-Time Adoption of New Accounting Standards or Interpretations from 2023](index=17&type=section&id=2023%20年起首次执行新会计准则或准则解释等涉及调整首次执行当年年初的财务报表) Effective January 1, 2023, the company adopted new accounting standards for deferred income tax, resulting in adjustments to opening consolidated and parent company balance sheets [Consolidated Balance Sheet (Adjustments)](index=17&type=section&id=Consolidated%20Balance%20Sheet%20%28Adjustments%29) Consolidated balance sheet opening balances were adjusted due to new accounting standards, increasing deferred tax assets by **CNY 557,364.73** and total equity by **CNY 9,852.10** - The company and its subsidiaries adopted the accounting treatment provisions in Interpretation No. 16 of the Accounting Standards for Business Enterprises, issued by the Ministry of Finance, regarding deferred income tax related to assets and liabilities arising from a single transaction, effective January 1, 2023, which no longer applies the initial recognition exemption[34](index=34&type=chunk) Consolidated Balance Sheet Adjustments (January 1, 2023) | Item | December 31, 2022 (CNY) | January 1, 2023 (CNY) | Adjustment (CNY) | | :--- | :--- | :--- | :--- | | Deferred tax assets | 1,889,849.85 | 2,447,214.58 | 557,364.73 | | Total Assets | 1,661,982,995.88 | 1,662,540,360.61 | 557,364.73 | | Deferred tax liabilities | - | 547,512.63 | 547,512.63 | | Total Liabilities | 239,933,834.13 | 240,481,346.76 | 547,512.63 | | Surplus reserve | 84,310,524.70 | 84,311,509.91 | 985.21 | | Retained earnings | 618,790,080.62 | 618,798,947.51 | 8,866.89 | | Total owners' equity attributable to parent company | 1,422,049,161.75 | 1,422,059,013.85 | 9,852.10 | | Total Liabilities and Owners' Equity | 1,661,982,995.88 | 1,662,540,360.61 | 557,364.73 | [Parent Company Balance Sheet (Adjustments)](index=20&type=section&id=Parent%20Company%20Balance%20Sheet%20%28Adjustments%29) Parent company balance sheet opening balances were adjusted due to new accounting standards, increasing deferred tax assets by **CNY 557,364.73** and total equity by **CNY 9,852.10** Parent Company Balance Sheet Adjustments (January 1, 2023) | Item | December 31, 2022 (CNY) | January 1, 2023 (CNY) | Adjustment (CNY) | | :--- | :--- | :--- | :--- | | Deferred tax assets | 1,941,554.23 | 2,498,918.96 | 557,364.73 | | Total Assets | 1,671,538,241.26 | 1,672,095,605.99 | 557,364.73 | | Deferred tax liabilities | - | 547,512.63 | 547,512.63 | | Total Liabilities | 240,857,835.93 | 241,405,348.56 | 547,512.63 | | Surplus reserve | 84,310,524.70 | 84,311,509.91 | 985.21 | | Retained earnings | 627,530,583.58 | 627,539,450.47 | 8,866.89 | | Total owners' equity | 1,430,680,405.33 | 1,430,690,257.43 | 9,852.10 | | Total Liabilities and Owners' Equity | 1,671,538,241.26 | 1,672,095,605.99 | 557,364.73 |